Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Trend topic
No spam. Unsubscribe anytime.
Pharmacy trend falls; specialty spend remains concentrated in a few high-cost drugs, vendors say
Summary
Vital1 and LP/UMR reports showed Q1 pharmacy trend dropped ~11% year-over-year while specialty therapies still account for a majority of spend; vendors pointed to fewer high-cost cystic fibrosis claims and increased biosimilar use as reasons for the specialty decline.
Vendor reports to the Sparks Group Health Care Committee showed pharmacy costs improved year-over-year but specialty drugs continue to drive most of the plan's pharmacy spending.
Jennifer Savas of Vital1 told the committee that overall plan cost per member per month was $237.69 in Q1 2026, an 11% drop from 2025. She said specialty therapies accounted for roughly 63.9% of overall spend but only about 1.9% of claims submitted. In a handoff to clinical staff, Derek Bergquist said specialty PMPM decreased about 18.8% quarter over quarter after a decline in several high-cost cystic fibrosis claims.
Bergquist highlighted program savings from the care improvement program, noting about $79,000 in savings and that outreach to providers led to statin initiation in about 17% of identified diabetic members who previously were not on appropriate statin therapy. He said diabetes remains the top driver of traditional drug spend while cardiovascular and pain/spasm classes followed.
UMR administrator Russ Garrett reported total claims processed through May numbered 21,741 with total paid ~$6.47 million for five months (about $4.1M medical, $1.9M Rx, $400K dental) and noted in-network utilization of 99.4% and an in-network savings rate of about 66.4%.
Vendor clarifications: Vital1 said generic dispense rate was about 86% and that the decline in specialty spend was partly due to a drop in a small number of high-cost fills; LP said some biosimilar utilization added to savings; UMR highlighted the plan's performance guarantees were met and that denial and duplicate claim handling explained a portion of denied claims.
